Epilepsy News and Research

Latest Epilepsy News and Research

Non-invasive trigeminal nerve stimulation shows promise in controlling seizures

Medications are the mainstay of treatment for epilepsy, but for a considerable number of patients - estimated to be as many as 1 million in the U.S. - drugs don't work. These patients suffer from a type of epilepsy known as refractory or drug-resistant epilepsy, in which drugs can't control their seizures.

26 May 2011

Study provides insight into effective treatments for autism spectrum disorder, seizures

Roughly 25-35% of individuals with autism eventually develop seizures and many of the remainder have subclinical seizure-like brain activity. However, little is known about which traditional epilepsy treatments and commonly used non-traditional alternative treatments are effective for treating seizures or epilepsy in children and adults with autism spectrum disorder.

25 May 2011

African-Americans with multiple sclerosis have lower vitamin D levels

African-Americans who have multiple sclerosis have lower vitamin D levels than African-Americans who don't have the disease, according to a study published in the May 24, 2011, print issue of Neurology, the medical journal of the American Academy of Neurology.

24 May 2011

Vertex receives FDA approval for INCIVEK to treat hepatitis C

Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has approved INCIVEK™ (telaprevir) tablets for a broad group of people with genotype 1 chronic hepatitis C with compensated liver disease (some level of damage to the liver but the liver still functions), including cirrhosis (scarring of the liver).

23 May 2011

Cholesterol drug may help treat mitochondrial diseases

A human drug that both prevents and cures kidney failure in mice sheds light on disabling human mitochondrial disorders, and may represent a potential treatment in people with such illnesses.

20 May 2011

American Academy of Neurology breaks ground for new headquarters, donates 1,000 children's bike helmets

The American Academy of Neurology will provide 1,000 free bike helmets for children who attend one of the many Bike Fests in north Minneapolis this summer, beginning with the first Bike Fest this Saturday, May 21, 2011. The donation coincides with today's groundbreaking ceremony for the Academy's new headquarters in Minneapolis, across from the Guthrie Theater.

20 May 2011

ViroPharma commences VP 20621 Phase 2 study for prevention of recurrent Clostridium difficile infection

ViroPharma Incorporated today announced initiation of a Phase 2 dose-ranging clinical study to evaluate the safety, tolerability, and efficacy of VP 20621 for prevention of recurrence of Clostridium difficile infection (CDI) in adults previously treated for CDI.

20 May 2011

Scientists identify 'de novo' genetic mutations in autism spectrum disorder children

Scientists at the University of Washington (UW) Department of Genome Sciences have identified several sporadic or "de novo" genetic mutations in children with autism spectrum disorder. The researchers applied leading edge molecular biology techniques and massively parallel sequencing to simultaneously examine all of the protein coding portions of the genome, collectively called the exome.

17 May 2011

Researcher says a comparison with epilepsy is an appropriate prism to view economics

Since 2008, the U.S. economy has been "seizing" uncontrollably. Now a Tel Aviv University researcher says that a comparison of the multifaceted economic downturn with the uncontrolled spasms of an epileptic is not inappropriate - and may say something about the origins of the disaster.

13 May 2011

Naurex announces completion of $18 million Series A financing

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced the completion of an $18 million Series A financing led by Adams Street Partners and Latterell Venture Partners.

11 May 2011

Genetic mutation linked to Kufs disease

According to a new study, a genetic mutation thought to be responsible for the rare hereditary brain disorder Kufs disease is finally identified. The research was carried out by Dr Melanie Bahlo and her team at the Walter and Eliza Hall Institute's bioinformatics department in Parkville, Australia, in partnership with neurologist and epilepsy specialists Professor Sam Berkovic and Dr Todor Arsov from the University of Melbourne, Australia.

10 May 2011

Dravet Syndrome Foundation awards OPKO Health grant to develop potential therapeutic agents

OPKO Health, Inc. announced today that it has been awarded a grant from the Dravet Syndrome Foundation to support the Company's efforts to develop potential therapeutic agents to treat a rare genetic disorder, Dravet Syndrome, also called severe myoclonic epilepsy of infancy, a severe form of epilepsy that usually appears during the first year of life.

9 May 2011

Ideal psychotropic drug may cause physical dependence

A report in the current issue of Psychotherapy and Psychosomatics by a group of European investigators headed by Fabrizio Schifano has explored the potential for dependence of pregabalin using patients' online reports.

9 May 2011

Scientists use new technologies to identify genetic cause of Kufs disease

Scientists from the Walter and Eliza Hall Institute and the University of Melbourne have used innovative new technologies to identify the gene responsible for a rare but fatal hereditary brain disorder. The discovery will make it possible to diagnose the disease through a blood test rather than a brain biopsy.

6 May 2011

Obesity during middle age may increase risk of developing dementia

According to a new study, being overweight or obese during middle age may increase the risk of certain dementias.

3 May 2011

Cyberonics initiates first implant of AspireSR product in epilepsy patients

Cyberonics, Inc., a global leader in epilepsy management, today announced the first implant of its AspireSR™ seizure response product on April 27, 2011.

3 May 2011

ETP makes investment to support development of ICVrx's targeted epilepsy drug technology

Epilepsy Therapy Project, a non-profit organization whose mission is to accelerate new therapies for people living with epilepsy and seizures, and ICVrx, LLC, a pharmacy product research and development company focused on novel therapies for central nervous system disorders, announced today that ETP has made an investment in ICVrx to support the development of ICVrx's targeted epilepsy drug technology for patients whose seizures are not controlled by current therapies.

30 Apr 2011

Epilepsy News and Research

Latest Epilepsy News and Research

Non-invasive trigeminal nerve stimulation shows promise in controlling seizures

Study provides insight into effective treatments for autism spectrum disorder, seizures

African-Americans with multiple sclerosis have lower vitamin D levels

Vertex receives FDA approval for INCIVEK to treat hepatitis C

Cholesterol drug may help treat mitochondrial diseases

American Academy of Neurology breaks ground for new headquarters, donates 1,000 children's bike helmets

ViroPharma commences VP 20621 Phase 2 study for prevention of recurrent Clostridium difficile infection

Scientists identify 'de novo' genetic mutations in autism spectrum disorder children

Researcher says a comparison with epilepsy is an appropriate prism to view economics

Naurex announces completion of $18 million Series A financing

Genetic mutation linked to Kufs disease

Dravet Syndrome Foundation awards OPKO Health grant to develop potential therapeutic agents

Ideal psychotropic drug may cause physical dependence

Scientists use new technologies to identify genetic cause of Kufs disease

Obesity during middle age may increase risk of developing dementia

Cyberonics initiates first implant of AspireSR product in epilepsy patients

ETP makes investment to support development of ICVrx's targeted epilepsy drug technology

Antiviral Drugs Advisory Committee recommends FDA to approve telaprevir for hepatitis C

ViroPharma reports net sales of $127 million for first quarter 2011

New study sheds light on how sleep-deprived lifestyles might impair brain function

Everything you need to know about epilepsy eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Epilepsy News and Research

Latest Epilepsy News and Research

Everything you need to know about epilepsy eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in